'The peptides specifically kill cancer cells without attacking healthy breast tissue cells.' ...

Approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 (CPS≥1) ...

Representative immunohistochemistry of GSII in gastric units to mark normal mucous neck cells (vehicle) and SPEM cells (72‐h HDT) in WT (top) and Atf3−/− (bottom) mice.

We next examined the distribution of cells considered components of oxyntic glands: surface mucous cells, parietal cells, chief cells and mucous neck cells. We did not strictly quantify surface mucous ...

Volrustomig is under clinical development by AstraZeneca and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC).

It is composed of type I cells and type II cells, which become excited by sympathetic and parasympathetic nerve fibers and release norepinephrine and acetylcholine. These characteristics give the ...

A Keytruda-based regimen given both before and after surgery for patients with head and neck squamous cell carcinoma may improve event-free survival.

The most prominent feature of the oesophagus was the presence of numerous mucous cells of different sizes, which were arranged at different levels of the epithelium and occupied almost the entire ...

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining ...

While therapeutically targeting mucus in young, vulnerable pancreatic cancer cells may have some advantages, it's a double-edged sword. When mucus production is blocked, cancer cells stop growing.